Haematological toxicity: a marker of adjuvant chemotherapy efficacy in stage II and III breast cancer.

[1]  C. Blomqvist,et al.  The prognosis of stage III breast cancer treated with postoperative radiotherapy and adriamycin-based chemotherapy with and without tamoxifen. Eight year follow-up results of a randomized trial. , 1995, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[2]  L. Norton,et al.  Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. , 1994, The New England journal of medicine.

[3]  B. Nilsson,et al.  Prednimustine (Sterecyt) versus cyclophosphamide both in combination with methotrexate and 5-fluorouracil in the treatment of advanced breast cancer. , 1993, European journal of cancer.

[4]  C. Blomqvist,et al.  The combination of radiotherapy, adjuvant chemotherapy (cyclophosphamide-doxorubicin-ftorafur) and tamoxifen in stage II breast cancer. Long-term follow-up results of a randomised trial. , 1992, British Journal of Cancer.

[5]  G. Hortobagyi,et al.  A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma , 1992, Cancer.

[6]  N. Geller,et al.  Association of disease‐free survival and percent of ideal dose in adjuvant breast chemotherapy , 1990, Cancer.

[7]  G. Bertelli,et al.  Impact of Administration‐Related Factors on Outcome of Adjuvant Chemotherapy for Primary Breast Cancer , 1989, American journal of clinical oncology.

[8]  G. Hortobagyi,et al.  Analysis of dose intensity in doxorubicin-containing adjuvant chemotherapy in stage II and III breast carcinoma. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  I. Tannock,et al.  A randomized trial of two dose levels of cyclophosphamide, methotrexate, and fluorouracil chemotherapy for patients with metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Gelman,et al.  Dose-response in the treatment of breast cancer: a critical review. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Rubens,et al.  A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma. , 1987, British Journal of Cancer.

[12]  G. Hortobagyi,et al.  Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Ratkin.  Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Gelman,et al.  Duration of therapy in adjuvant chemotherapy trials. , 1986, NCI monographs : a publication of the National Cancer Institute.

[15]  R. Cooper.  Combination chemotherapy of breast cancer. , 1985, The Mount Sinai journal of medicine, New York.

[16]  W. Hryniuk,et al.  The importance of dose intensity in chemotherapy of metastatic breast cancer. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. K. Knight,et al.  A controlled trial of adjuvant chemotherapy with melphalan versus cyclophosphamide, methotrexate, and fluorouracil for breast cancer. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[18]  H. Mouridsen,et al.  Adjuvant systemic therapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group's trials of cyclophosphamide or CMF in premenopausal and tamoxifen in postmenopausal patients. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[19]  H. Senn,et al.  Adjuvant chemoimmunotherapy with LMF + BCG in node-negative and node-positive breast cancer: 8 year results. , 1984, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[20]  C. Redmond,et al.  The methodologic dilemma in retrospectively correlating the amount of chemotherapy received in adjuvant therapy protocols with disease-free survival. , 1983, Cancer treatment reports.

[21]  R. Gelman,et al.  Prospective evaluation of rotating chemotherapy in advanced breast cancer. An Eastern Cooperative Oncology Group Trial. , 1983, American journal of clinical oncology.

[22]  G. Bonadonna,et al.  Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  B. Hoogstraten,et al.  Combination chemotherapy (CMFVP) versus L‐phenylalanine mustard (L‐PAM) for operable breast cancer with positive axillary nodes. A southwest oncology group study , 1982, Cancer.

[24]  J. O'fallon,et al.  A preliminary assessment of factors associated with recurrent disease in a surgical adjuvant clinical trial for patients with breast cancer with special emphasis on the aggressiveness of therapy , 1982, American journal of clinical oncology.

[25]  G. Hortobagyi,et al.  Combination chemotherapy for breast cancer metastatic to bone marrow , 1981, Cancer.

[26]  G. Bonadonna,et al.  Dose-response effect of adjuvant chemotherapy in breast cancer. , 1981, The New England journal of medicine.

[27]  D.,et al.  Regression Models and Life-Tables , 2022 .